Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
6 Results for "
hyperuricemia rat model
" in MedChemExpress (MCE) Product Catalog:
Products (6)
6 Results for "hyperuricemia rat model" in MCE Product Catalog:
Cat. No.: HY-178342
Research Areas:
Xanthine oxidase-IN-18 is a potent orally activeXanthine oxidase (XO) inhibitor (IC50 = 0.263 μM). Xanthine oxidase-IN-18 exerts inhibition by directly and stably binding to the xanthine oxidase Mo-co active site. Xanthine oxidase-IN-18 exhibits reactive oxygen species (ROS) scavenging activity. Xanthine oxidase-IN-18 shows anti-hyperuricemia effects in a Potassium oxonate (HY-17511)-induced hyperuricemic rat model. Xanthine oxidase-IN-18 can be used for hyperuricemia, breast and lung cancer research .
Cat. No.: HY-179030
CAS No.: 3055301-22-6
Target:
Research Areas:
Xanthine oxidase-IN-19 (Compound 13i) is an orally effective inhibitor of xanthine oxidase (XO), with an IC50 of 0.2 μM. Xanthine oxidase-IN-19 can significantly reduce serum uric acid levels in acute hyperuricemia rat models. Xanthine oxidase-IN-19 can be used for the study of acute hyperuricemia .
Target:
Research Areas:
URAT1&XO inhibitor 1 (compound 29) is a dual inhibitor of both URAT1 (IC50=~10 μM) and Xanthine Oxidase (IC50=1.01 μM). URAT1&XO inhibitor 1 results hypouricemic effect in potassium oxonate-induced hyperuricemia rat model. URAT1&XO inhibitor 1 is used for hyperuricemia research .
Cat. No.: HY-180186
CAS No.: 3069916-11-3
Target:
Research Areas:
Xanthine oxidase-IN-20 is a potent and orally active xanthine oxidase (XO) inhibitor with an IC50 of 1.7 nM. Xanthine oxidase-IN-20 exhibits outstanding serum uric acid (SUA)-lowering efficacy in both mouse and rat acute hyperuricemia models. Xanthine oxidase-IN-20 shows favorable safety profile. Xanthine oxidase-IN-20 can be used for hyperuricemia and gout research .
Cat. No.: HY-189143
Target:
Research Areas:
Xanthine oxidase-IN-24 is an orally active mixed-type inhibitor of xanthine oxidase, with an IC50 of 0.051 μM and a Ki of 0.162 μM. Xanthine oxidase-IN-24 interacts with both free xanthine oxidase and the xanthine-xanthine oxidase complex, and reduces uric acid production in vivo. In a rat model of hyperuricemia induced by Potassium oxonate (HY-17511), Xanthine oxidase-IN-24 dose-dependently lowers serum uric acid levels, improves renal function-related biochemical parameters such as creatinine and urea nitrogen, and alleviates histopathological damage to liver and kidney tissues. Xanthine oxidase-IN-24 can be used in the research of hyperuricemia .
Cat. No.: HY-189695
CAS No.: 3133114-23-2
Target:
Research Areas:
URAT1-IN-18 is an orally effective URAT1 inhibitor. URAT1-IN-18 inhibits URAT1-mediated urate transport and renal urate reabsorption. URAT1-IN-18 exhibits low cytotoxicity in vitro, with less apoptosis and loss of mitochondrial membrane potential. URAT1-IN-18 shows moderate metabolic stability in rat liver microsomes. URAT1-IN-18 reduces serum uric acid levels in a hyperuricemia mouse model, protects renal tubular structure, and has good biosafety. URAT1-IN-18 can be used for research related to hyperuricemia .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
